WATERTOWN, Mass.--(BUSINESS WIRE)--
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained
release, drug delivery products for treatment of back-of-the-eye
diseases, today announced that its financial results for the fourth
quarter and fiscal year 2013 will be released after the market close on
Wednesday, September 25, 2013, followed the same day by a conference
call and live webcast scheduled for 4:30 p.m. ET.
The conference call may be accessed by dialing (877) 312-7505 from the
U.S. and Canada, or (631) 813-4828 from international locations. A live
webcast will be available on the Investor Relations section of the
corporate website at http://www.psivida.com.
A replay of the call will be available beginning September 25, 2013 at
approximately 7:30 p.m. ET and ending on October 2, 2013. The replay may
be accessed by dialing (855) 859-2056 within the U.S. and Canada or
(404) 537-3406 from international locations, Conference ID Number:
68809431. A replay of the webcast will also be available on the
corporate website during that time.
About pSivida Corp.
pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained
release, drug delivery products designed to deliver drugs at a
controlled and steady rate for months or years. pSivida is currently
focused on treatment of chronic diseases of the back of the eye
utilizing its core technology systems, Durasert™ and BioSilicon™. The
injectable, sustained release micro-insert ILUVIEN® for the treatment of
chronic DME, licensed to Alimera Sciences, Inc., has received marketing
authorization in Austria, France, Germany, Portugal, Spain and the U.K.
and is awaiting authorization in Italy. ILUVIEN for DME has not been
approved in the U.S. pSivida has begun pivotal Phase III clinical trials
for the treatment of posterior uveitis, a chronic back-of-the-eye
disease, with the same micro-insert as ILUVIEN for DME. An
investigator-sponsored clinical trial is ongoing for an injectable,
bioerodible micro-insert to treat glaucoma and ocular hypertension.
pSivida's FDA-approved Retisert® licensed to Bausch & Lomb Incorporated
provides long-term, sustained drug delivery to posterior uveitis.
Follow pSivida on social media:
Twitter: https://twitter.com/pSividaCorp
Facebook: https://www.facebook.com/pages/PSivida-Corp/544893792199562
LinkedIn: http://www.linkedin.com/company/psivida
Google+: https://plus.google.com/u/0/b/113754643626984244726/113754643626984244726/posts
The President's Blog: http://www.thechairmansblog.com/paul-ashton
For more information on pSivida, visit www.psivida.com.
In US:
Martin E. Janis & Company, Inc.
Beverly Jedynak
President
Tel:
+1 (312) 943 1123
bjedynak@janispr.com
or
In
Australia:
pSivida Corp.
Brian Leedman
Vice President,
Investor Relations
+61 (0) 41 228 1780
brianl@psivida.com
Source: pSivida Corp.
News Provided by Acquire Media
